AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 APR 9 - (NewsRx.com & NewsRx.net) -- Chemoimmunotherapy was more effective in mice carrying HPV16-associated, MHC class I+ tumors than in those carrying and class I- tumors.
According to recent research from Czech Republic, "The effectiveness of chemoimmunotherapy with ifosfamide derivative CBM-4A and recombinant IL-2, IL-12, GM-CSF, or genetically modified, cytokine-producing tumor vaccines was examined in mice carrying HPV16-associated, MHC class I+ (TC-1), and MHC class P (MK16) tumors. Intraperitoneal treatment of TC-1 or MK16 tumor-bearing g mice with CBM-4A produced a significant tumor-inhibitory effect."
"When the i.p. treatment of the MHC class I+ TC-1 tumor-bearing mice with CBM-4A was followed by peritumoral s.c. administration of IL-2, IL-12, or both cytokines, the growth of TC1 tumors was inhibited more vigorously than after the chemotherapy alone," reported M. Indrova and colleagues at the Academy of Sciences of the Czech Republic. "In contrast, when the i.p. treatment of the MHC class P MK16 tumor-bearing mice with CBM-4A was followed by peritumoral s.c. administration of IL-2 or IL-12, the cytokine therapy had no potentiating effect. The only potentiating effect of the MK16 tumor immunotherapy was obtained when the i.p. CBM-4A pretreatment was followed by peritumoral s.c. administration of IL-2 plus IL-12."
"In further experiments, the TC-1 and MK16 tumor-bearing mice were i.p. pretreated with CBM-4A and then injected s.c., peritumorally, with genetically modified, IL-2 or GM-CSF-producing MK16 tumor vaccines," the researchers stated. "Whereas both genetically modified tumor vaccines produced a substantial tumor-inhibitory effect in mice carrying TC-1 tumors, no effect of the vaccines was ...
Source: HighBeam Research, HPV16-associated, MHC class I+ tumors more susceptible than class I-...